Furthermore, tumors harboring ARID1A mutations may exhibit high microsatellite instability (MSI-H) or high tumor mutation burden (TMB), potentially rendering them responsive to immune checkpoint inhibitors such as pembrolizumab and nivolumab [81]. Here, ARID1A is linked to neoplasm.